SCHEMBL10047701

SCHEMBL10047701

COC(=O)CCCC[C@@H]1SCC2NC(=O)N[C@@H]21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 8/20 1.00
L3MBTL1 Q9Y468 2/20 0.71
MEN1 O00255 1/20 0.71
ABL1 P00519 1/20 0.71
LMNA P02545 1/20 0.71
PKM P14618 1/20 0.71
IDE P14735 1/20 0.71
MAPK1 P28482 1/20 0.71
KMT2A Q03164 1/20 0.71
RIN1 Q13671 1/20 0.71
HLCS P50747 6/20 0.64
CA12 O43570 3/20 0.54
CA1 P00915 3/20 0.54
CA2 P00918 3/20 0.54
CA9 Q16790 3/20 0.54
HPSE Q9Y251 1/20 0.54
PPARG P37231 2/20 0.52
NR2E3 Q9Y5X4 2/20 0.52
NCOR2 Q9Y618 2/20 0.52
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19170150 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA
SCHEMBL10047674 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA
SCHEMBL132274 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA
SCHEMBL565879 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA
SCHEMBL10171691 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA
SCHEMBL19267509 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA
SCHEMBL20216901 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA
SCHEMBL21488759 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA
SCHEMBL20844951 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA
SCHEMBL14617995 1.00 TDP1 (1.00) TDP1L3MBTL1MEN1ABL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9670255-B2 Modified biotin, mutant streptavidin, and use thereof SAVID THERAPEUTICS INC. (JP) 2017-06-06 US disclosed
US-20160137704-A1 MODIFIED BIOTIN, MUTANT STREPTAVIDIN, AND USE THEREOF SAVID THERAPEUTICS INC. (JP) 2016-05-19 US disclosed
US-20120083599-A1 Biomolecular Labelling Using Multifunctional Biotin Analogues UNIVERSITY OF NOTTINGHAM (GB) 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083599-A1 Biomolecular Labelling Using Multifunctional Biotin Analogues BTD, URB2, RAET1L TDP1 4767/4885L3MBTL1 469/4885MEN1 3602/4885
US-20160137704-A1 MODIFIED BIOTIN, MUTANT STREPTAVIDIN, AND USE THEREOF BTD, HLCS, BSG TDP1 3582/4885L3MBTL1 660/4885MEN1 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.